We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
AJOVY Teva Pharma Australia Pty Ltd
Product name
AJOVY
Sponsor
Accepted date
Oct-2025
Active ingredients
Fremanezumab
Summary of proposed indication
Ajovy (fremanezumab) is proposed as a preventive treatment of episodic migraine (less than 15 migraines per month) in children aged 6 years and older, weighing at least 45 kg.
Application type
C (new indication)
Publication date
Oct-2025